McKesson Corp. and HCA Healthcare Inc. announced an agreement to combine McKesson’s US Oncology Research and HCA Healthcare’s Sarah Cannon Research Institute.
The Richard K. Lubin Family Foundation will provide a grant to establish the Lubin Family Foundation Scholar Awards at Dana-Farber Cancer Institute.
Photo credit: TANGRYSTAN, BrystkreftforeningenThe world’s first statue of a woman with incurable breast cancer—Cecilie, a 44-year-old mother of three—was unveiled at Eidsvoll Square, in front of Stortinget, the Norwegian Parliament, on June 20.
Texas Oncology broke ground on a 32,000-square foot cancer care center located on the CHRISTUS Southeast Texas St. Elizabeth hospital campus.
For the past several years, interest in FLASH radiation therapy research has surged in the oncology community.1 It is arguably one of the hottest topics in cancer care today, with the potential to shift the trajectory of treatment in ways that were once only imaginable.
A report led by researchers at the American Cancer Society, in collaboration with NCI, showed that more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were living in the United States as of Jan. 1, 2022, with over 12 million (67%) aged 65 years or older.
Researchers at Winship Cancer Institute of Emory University found that COVID-19 vaccines are much less effective for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, particularly those ages 65 and older. After vaccination, many of these patients produced low or no antibodies that bind or neutralize SARS-CoV-2 and its variants of concern, particularly Omicron.
University of Texas Southwestern researchers developed a blood test to predict which nonalcoholic fatty liver disease patients are most likely to develop hepatocellular carcinoma.
Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
FDA has granted accelerated approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
